Fairvalue-Calculator Fairvalue-Calculator
EN DE

LAUNXP Biomedical Co (6876) Fair Value & Analysis

Healthcare · TW · Market cap 1.2B TWD

Price16.65 TWD
Fair Value4.62 TWD
Upside-72.3%
Quality88/100
Evidence: Low Range 3.46 TWD – 5.77 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

LAUNXP Biomedical Co (6876) currently trades at 16.65 TWD, while our model-based Fair Value estimate is 4.62 TWD — implying the stock looks roughly 72.3% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is LAUNXP Biomedical Co (6876) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 4.62 TWD versus a price of 16.65 TWD — about −72% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6876?
Our 21-model fair value for LAUNXP Biomedical Co is 4.62 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 16.65 TWD.
What is the quality score of 6876?
LAUNXP Biomedical Co has a Quality Score of 88/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.